Evidence map›Paper›PMID 26267355›Full record

ArticlePloS one2015

Synthesis and evaluation of chloramphenicol homodimers: molecular target, antimicrobial activity, and toxicity against human cells.

Ourania N Kostopoulou, George E Magoulas, Georgios E Papadopoulos, Athanasia Mouzaki, George P Dinos, Dionissios Papaioannou, Dimitrios L Kalpaxis

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Strategic re-engineering of antibiotics.Nature reviews bioengineering · 2025
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ourania N KostopoulouDepartment of Biochemistry, School of Medicine, University of Patras, Patras, Greece.
George E MagoulasLaboratory of Synthetic Organic Chemistry, Department of Chemistry, University of Patras, Patras, Greece.
Georgios E PapadopoulosDepartment of Biochemistry and Biotechnology, University of Thessaly, Ploutonos, Larissa, Greece.
Athanasia MouzakiDivision of Hematology, Department of Internal Medicine, School of Medicine, University of Patras, Patras, Greece.
George P DinosDepartment of Biochemistry, School of Medicine, University of Patras, Patras, Greece.
Dionissios PapaioannouLaboratory of Synthetic Organic Chemistry, Department of Chemistry, University of Patras, Patras, Greece.
Dimitrios L KalpaxisDepartment of Biochemistry, School of Medicine, University of Patras, Patras, Greece.
University of Patras · GRUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As fight against antibiotic resistance must be strengthened, improving old drugs that have fallen in reduced clinical use because of toxic side effects and/or frequently reported resistance, like chloramphenicol (CAM), is of special interest. Chloramphenicol (CAM), a prototypical wide-spectrum antibiotic has been shown to obstruct protein synthesis via binding to the bacterial ribosome. In this study we sought to identify features intensifying the bacteriostatic action of CAM. Accordingly, we synthesized a series of CAM-dimers with various linker lengths and functionalities and compared their efficiency in inhibiting peptide-bond formation in an Escherichia coli cell-free system. Several CAM-dimers exhibited higher activity, when compared to CAM. The most potent of them, compound 5, containing two CAM bases conjugated via a dicarboxyl aromatic linker of six successive carbon-bonds, was found to simultaneously bind both the ribosomal catalytic center and the exit-tunnel, thus revealing a second, kinetically cryptic binding site for CAM. Compared to CAM, compound 5 exhibited comparable antibacterial activity against MRSA or wild-type strains of Staphylococcus aureus, Enterococcus faecium and E. coli, but intriguingly superior activity against some CAM-resistant E. coli and Pseudomonas aeruginosa strains. Furthermore, it was almost twice as active in inhibiting the growth of T-leukemic cells, without affecting the viability of normal human lymphocytes. The observed effects were rationalized by footprinting tests, crosslinking analysis, and MD-simulations.

Indexed as

DimerizationAnti-Infective AgentsCell-Free SystemChloramphenicolDrug Resistance, MicrobialEscherichia coliHumansLymphocytesMolecular Dynamics SimulationProtein BiosynthesisPseudomonas aeruginosaRibosomesStaphylococcus aureusAnti-Infective AgentsChloramphenicol

Identifiers

PMID26267355
PMCPMC4533973
OpenAlexW2286919735

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.